Ketoconazole-loaded PLGA nanoparticles and their synergism against Candida albicans when combined with silver nanoparticles

Sadozai, Sajid Khan; Khan, Saeed Ahmad; Becker, Daniel; Steinbrück, Nils; Gier, Stefanie; Baseer, Abdul; Breinig, Frank; Kickelbick, Guido; Schneider, Marc

doi:10.1016/j.jddst.2020.101574

Cited by 23 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, efforts have been made to develop novel strategies for an optimal delivery of antifungal combinations in the human body. For example, Sadozai and colleagues created ketoconazole-loaded poly (lactide-co-glycolide) nanoparticles to increase ketoconazole’s bioavailability as these nanoparticles may assemble in wrinkles and hair follicles, resulting in a prolonged ketoconazole release to the skin tissue [ 283 ]. This ketoconazole-loaded poly (lactide-co-glycolide) nanoparticles acted synergistically with silver nanoparticles against planktonic C. albicans cultures [ 283 ].…”

Section: Discussionmentioning

confidence: 99%

Combination Therapy to Treat Fungal Biofilm-Based Infections

Tits

Cammue

Thevissen

2020

IJMS

View full text Add to dashboard Cite

An increasing number of people is affected by fungal biofilm-based infections, which are resistant to the majority of currently-used antifungal drugs. Such infections are often caused by species from the genera Candida, Aspergillus or Cryptococcus. Only a few antifungal drugs, including echinocandins and liposomal formulations of amphotericin B, are available to treat such biofilm-based fungal infections. This review discusses combination therapy as a novel antibiofilm strategy. More specifically, in vitro methods to discover new antibiofilm combinations will be discussed. Furthermore, an overview of the main modes of action of promising antibiofilm combination treatments will be provided as this knowledge may facilitate the optimization of existing antibiofilm combinations or the development of new ones with a similar mode of action.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination Therapy to Treat Fungal Biofilm-Based Infections

Tits

Cammue

Thevissen

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…For the isolation of dry NPs, the NPs dispersion was centrifuged at 15,000 RCF for 30 minutes using (REMI equipment) after overnight evaporation of DCM. The pellet was dispersed in de-ionized water before being freeze-dried with a (Vir Tis bencbtop K) freeze drier [23].…”

Section: Formulation Of Miconazole Nitrate Loaded Nanoparticle By Emulsification / Solvent Evaporation Methodsmentioning

confidence: 99%

“…The spectrum was scanned over frequency range 4000-400cm-1 in FTIR instrument Shimadzu IRAffinity-1S. The spectral analysis was done, by standard absorbance of the functional groups [23].…”

Section: Ftir Spectrummentioning

confidence: 99%

“…Small amount of Miconazole Nitrate (2 to 3 mg) was accurately balanced in aluminum pan, hermetically sealed with the help of crimper and sample pan and reference pan are kept in DSC analyzer than Sample was heated from ambient temperature 40 0 C to 400 0 C, with the heating rate of 10 0 C/min. Inert atmospheres was provided by purging nitrogen gas flowing at 100 ml/min [23].…”

Section: Differential Scanning Calorimetry (Dsc) Studiesmentioning

confidence: 99%

“…X1 levels of 5, 75, and 100 mg were chosen, whereas X2 levels of 2, 4, and 6 ml were chosen. Entrapment efficiency (Y1) and particle size were the dependent or response variables (Y2) [23][24][25][26][27][28]. Optimization formula shows in Table 2.…”

Section: Optimization Of Formulationmentioning

confidence: 99%

See 2 more Smart Citations

Formulation and Evaluation of Miconazole Nitrate Loaded Nanoparticles for Topical Delivery

Pawar¹,

Jadhav

Ahire³

et al. 2021

JPRI

View full text Add to dashboard Cite

The aim of the present work was to formulate and evaluate Miconazole nitrate (MN) polymeric nanoparticles (NPs) for systemic delivery of the active ingredient after topical administration. The Solvent evaporation approach was used to make nanoparticles for topical delivery of MN. Particle size, entrapment efficiency and SEM were all measured in MN-SLN. A consistent size distribution (PI 0.300) was used to generate aqueous NPs dispersions with a mean particle size less than 250 nm. After 3 months of storage, the produced semi-solid systems had a mean particle size of less than 250 nm and a PI of less than 0.500. The F5 formulation was been chosen as the model formulation from among the nine nanoparticle formulations developed (F1 to F9). The reason for this was that, according to the ICH stability guidelines, formulation F5 was judged to be optimal and stable. The F5 formulations of miconazole nanoparticles shows the highest entrapment efficiency (93.28%) and drug loading (86.64%). In conclusion, there are two major advantages of using miconazole nanoparticle drug delivery systems. i.e., they are topical preparations that assemble in the hair follicles and wrinkles to produce a systemic and local action. It is possible that nanoparticles will be the most effective treatment for fungal skin infections.

show abstract

Development of mucoadhesive modified kappa‐carrageenan/pectin patches for controlled delivery of drug in the buccal cavity

et al. 2021

View full text Add to dashboard Cite

In this study, modified kappa-carrageenan/pectin hydrogel patches were fabricated for treatment of buccal fungal infections. For this purpose, kappa-carrageenan-gacrylic acid was modified with different thiolated agents (L-cysteine and 3-mercaptopropionic acid), and the thiol content of the resulting modified kappacarrageenan was confirmed by elemental analyzer. Then, the hydrogel patches were fabricated, and characterized by Fourier-transform infrared spectroscopy, thermogravimetric analysis, ex vivo mucoadhesion test, and swelling behavior.Triamcinolone acetonide was added either directly or by encapsulating within the poly(lactic-co-glycolic acid) nanoparticles. The release amount of the drug from the directly loaded patch was 7.81 mg/g polymer, while it was 3.28 mg/g polymer for the encapsulated patch with the same content at 7 hr. The hydrogel patches had no cytotoxicity by cell culture studies. Finally, the drug loaded hydrogel patches were demonstrated antifungal activity against Aspergillus fumigatus and Aspergillus flavus.These results provide that the novel modified kappa-carrageenan and pectin based buccal delivery system has promising antifungal property, and could have advantages compared to conventional buccal delivery systems.antifungal activity, buccal drug delivery, thiolated kappa-carrageenan, triamcinolone acetonide | INTRODUCTIONUlcerative diseases in the mucous membrane of the buccal cavity are observed as a result of a wide etiological reasons such like infections, traumas, immunological disorders, or side effects of some drugs. 1,2 Amongst these, mucocutaneous diseases are observed frequently such as lichen planus, 3 aphthous stomatitis, 4 erythema multiforme, and Behçet's disease. 5 Conventional drug applied to the oral mucosa are generally in the form of in situ gels, 6 pastes, 7 or mouthwashes. 8 These forms have some drawbacks due to causing high-level drug concentration and in the oral cavity for a short period of time. 9 Therefore, the desired therapeutic drug concentration for mucosal and transmucosal absorption could not be adequately provided for healing. To overcome the limitations of the conventional delivery systems, use of oral mucoadhesive systems in the topical treatment of oral ulcerative diseases is a more rational approach. The oral mucoadhesive systems could be prepared in various forms such as buccal adhesive patches, films, and tablets. 10,11

show abstract

Ketoconazole-loaded PLGA nanoparticles and their synergism against Candida albicans when combined with silver nanoparticles

Cited by 23 publications

References 34 publications

Combination Therapy to Treat Fungal Biofilm-Based Infections

Combination Therapy to Treat Fungal Biofilm-Based Infections

Formulation and Evaluation of Miconazole Nitrate Loaded Nanoparticles for Topical Delivery

Development of mucoadhesive modified kappa‐carrageenan/pectin patches for controlled delivery of drug in the buccal cavity

Contact Info

Product

Resources

About